[go: up one dir, main page]

LU92699I2 - Bazédoxifène, éventuellement sous la forme d'un sel pharmaceutiquement, acceptable tel que le sel d'acétate, et d'estrogènes conjugués - Google Patents

Bazédoxifène, éventuellement sous la forme d'un sel pharmaceutiquement, acceptable tel que le sel d'acétate, et d'estrogènes conjugués Download PDF

Info

Publication number
LU92699I2
LU92699I2 LU92699C LU92699C LU92699I2 LU 92699 I2 LU92699 I2 LU 92699I2 LU 92699 C LU92699 C LU 92699C LU 92699 C LU92699 C LU 92699C LU 92699 I2 LU92699 I2 LU 92699I2
Authority
LU
Luxembourg
Prior art keywords
bazedoxifene
optionally
pharmaceutically acceptable
salt
conjugated estrogens
Prior art date
Application number
LU92699C
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22151320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92699(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of LU92699I2 publication Critical patent/LU92699I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
LU92699C 1998-05-15 2015-04-24 Bazédoxifène, éventuellement sous la forme d'un sel pharmaceutiquement, acceptable tel que le sel d'acétate, et d'estrogènes conjugués LU92699I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7956198A 1998-05-15 1998-05-15

Publications (1)

Publication Number Publication Date
LU92699I2 true LU92699I2 (fr) 2015-06-24

Family

ID=22151320

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92699C LU92699I2 (fr) 1998-05-15 2015-04-24 Bazédoxifène, éventuellement sous la forme d'un sel pharmaceutiquement, acceptable tel que le sel d'acétate, et d'estrogènes conjugués

Country Status (42)

Country Link
EP (1) EP1076558B1 (fr)
JP (3) JP2002515431A (fr)
KR (1) KR100620772B1 (fr)
CN (1) CN1230163C (fr)
AP (1) AP1424A (fr)
AR (1) AR020074A1 (fr)
AT (1) ATE245026T1 (fr)
AU (1) AU760378B2 (fr)
BE (1) BE2015C026I2 (fr)
BG (1) BG64783B1 (fr)
BR (1) BR9911040A (fr)
CA (1) CA2329530A1 (fr)
CU (1) CU23241B7 (fr)
CY (1) CY2015020I1 (fr)
CZ (1) CZ299334B6 (fr)
DE (1) DE69909616T2 (fr)
DK (1) DK1076558T3 (fr)
EA (1) EA005932B1 (fr)
EE (1) EE04262B1 (fr)
ES (1) ES2203131T3 (fr)
FR (1) FR15C0035I2 (fr)
GE (1) GEP20033079B (fr)
HK (1) HK1031691A1 (fr)
HR (1) HRP20000778B1 (fr)
HU (2) HU226587B1 (fr)
ID (1) ID26890A (fr)
IL (1) IL139130A (fr)
IN (1) IN192220B (fr)
LT (1) LTC1076558I2 (fr)
LU (1) LU92699I2 (fr)
NO (2) NO328129B1 (fr)
NZ (1) NZ508200A (fr)
OA (1) OA11552A (fr)
PL (1) PL194750B1 (fr)
PT (1) PT1076558E (fr)
SI (1) SI1076558T1 (fr)
SK (1) SK284666B6 (fr)
TR (1) TR200003377T2 (fr)
TW (1) TW565554B (fr)
UA (1) UA66861C2 (fr)
WO (1) WO1999059581A1 (fr)
ZA (1) ZA200006959B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1424A (en) * 1998-05-15 2005-06-06 Wyeth Corp 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens.
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
AU5957500A (en) 1999-07-06 2001-01-22 Endorecherche Inc. Methods of treating and/or suppressing weight gain
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
WO2002003989A2 (fr) * 2000-07-06 2002-01-17 Wyeth Therapie permettant d'inhiber l'incontinence du sphincter
US6455568B2 (en) 2000-07-06 2002-09-24 Wyeth Combination therapy for inhibiting sphincter incontinence
AU2001271784A1 (en) * 2000-07-06 2002-01-21 Wyeth Therapy for prosthesis-related bone degeneration
AU2001273125A1 (en) * 2000-07-06 2002-01-21 American Home Products Corporation Combinations of bisphosphonates, estrogenic agents and optionally estrogens
CN1468110A (zh) * 2000-07-06 2004-01-14 惠氏公司 他汀类、雌激素药物以及任选雌激素的联合应用
US6376486B1 (en) 2000-07-06 2002-04-23 American Home Products Corporation Methods of inhibiting sphincter incontinence
DE10117441A1 (de) * 2001-04-03 2002-10-10 Schering Ag 1-Indolylderivate, deren Verwendung zur Herstellung von Arzneimitteln, ein Verfahren zur Herstellung der 1-Indolylderivate sowie 1-Indolylderivate enthaltende pharmzeutische Präparate
KR100567718B1 (ko) 2001-07-31 2006-04-05 화이자 프로덕츠 인크. 에스트로겐 작용제/길항제와 에스트로겐과 프로게스틴의조합을 포함하는 약학 조성물, 키트 및 방법
KR100470274B1 (ko) 2002-11-08 2005-02-05 진 장 덮개층을 이용한 비정질 물질의 상 변화 방법
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
CN102066323B (zh) 2008-04-16 2015-05-13 卡罗生物股份公司 新的雌激素受体配体
AR072297A1 (es) * 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
GB201113538D0 (en) 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
CN102690225B (zh) * 2012-04-11 2014-12-24 南京友杰医药科技有限公司 巴多昔芬的合成方法
CN103709090A (zh) * 2014-01-16 2014-04-09 江苏万特制药有限公司 醋酸巴多昔芬的制备方法及其关键中间体
CN103739540B (zh) * 2014-01-20 2016-05-04 华润赛科药业有限责任公司 一种醋酸巴多昔芬中间体的制备方法
CN105669518B (zh) * 2014-12-04 2019-06-04 上海医药集团股份有限公司 醋酸巴多昔芬及其a晶型的制备方法
US12030878B2 (en) 2017-12-15 2024-07-09 Bristol-Myers Squibb Company Substituted indole ether compounds
IT201800006562A1 (it) * 2018-06-21 2019-12-21 Procedimento e intermedi utili per la preparazione di indoli
CN115380026B (zh) * 2020-03-17 2023-11-07 南京明德新药研发有限公司 蛋白降解调节剂与其使用方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
EP0639567A1 (fr) * 1992-05-08 1995-02-22 Otsuka Pharmaceutical Factory, Inc. Derive d'indole
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
GB9326332D0 (en) * 1993-12-23 1994-02-23 Karo Bio Indole derivatives
DE4426625A1 (de) * 1994-07-27 1996-03-14 Schering Ag 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
TW397821B (en) * 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
NZ314601A (en) * 1996-04-19 1999-09-29 American Home Prod 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole derivatives as estrogenic agents and pharmaceutical compositions
ATE277037T1 (de) * 1996-07-09 2004-10-15 Nikem Research Srl Indolderivate zur behandlung von osteoporose
US5672609A (en) * 1996-07-18 1997-09-30 Eli Lilly And Company Pyridine compounds, intermediates compositions and methods of use
SK286460B6 (sk) * 1997-10-15 2008-10-07 Wyeth Aryloxyalkyldialkylamínové zlúčeniny a spôsob ichvýroby
CA2308069A1 (fr) * 1997-10-28 1999-05-06 Merck & Co., Inc. Antagonistes de la gonadoliberine
ID24568A (id) * 1997-11-06 2000-07-27 American Home Prod Kontrasepsi oral yang mengandung anti-estrogen plus progestin
AP1424A (en) * 1998-05-15 2005-06-06 Wyeth Corp 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens.

Also Published As

Publication number Publication date
EA200001193A1 (ru) 2001-12-24
ATE245026T1 (de) 2003-08-15
SK284666B6 (sk) 2005-08-04
AU3894499A (en) 1999-12-06
BR9911040A (pt) 2001-02-13
EE04262B1 (et) 2004-04-15
BE2015C026I2 (en) 2018-08-24
WO1999059581A1 (fr) 1999-11-25
SI1076558T1 (en) 2003-10-31
ES2203131T3 (es) 2004-04-01
HU226587B1 (en) 2009-04-28
CZ20004254A3 (cs) 2001-12-12
HUP0103096A2 (hu) 2002-05-29
IL139130A (en) 2005-11-20
UA66861C2 (uk) 2004-06-15
OA11552A (en) 2004-06-07
KR100620772B1 (ko) 2006-09-13
HRP20000778B1 (en) 2004-10-31
BG64783B1 (bg) 2006-04-28
CN1326347A (zh) 2001-12-12
JP2009019042A (ja) 2009-01-29
SK17202000A3 (sk) 2001-07-10
AU760378B2 (en) 2003-05-15
NO2015015I2 (no) 2015-06-02
FR15C0035I2 (fr) 2015-08-28
AP2000001970A0 (en) 2000-12-31
ZA200006959B (en) 2001-11-27
JP2014159472A (ja) 2014-09-04
PL345268A1 (en) 2001-12-03
IN192220B (fr) 2004-03-20
GEP20033079B (en) 2003-10-27
NO328129B1 (no) 2009-12-14
HUP0103096A3 (en) 2002-11-28
EP1076558B1 (fr) 2003-07-16
CY2015020I1 (el) 2020-05-29
LTC1076558I2 (lt) 2016-11-10
AP1424A (en) 2005-06-06
NO20005770L (no) 2001-01-12
JP5607871B2 (ja) 2014-10-15
BG104930A (en) 2001-07-31
EP1076558A1 (fr) 2001-02-21
TW565554B (en) 2003-12-11
NZ508200A (en) 2003-09-26
TR200003377T2 (tr) 2001-03-21
DK1076558T3 (da) 2003-11-03
NO2015015I1 (no) 2015-06-02
CA2329530A1 (fr) 1999-11-25
CU23241B7 (es) 2007-10-17
NO20005770D0 (no) 2000-11-14
ID26890A (id) 2001-02-15
PT1076558E (pt) 2003-11-28
DE69909616T2 (de) 2004-06-17
EE200000652A (et) 2002-04-15
CN1230163C (zh) 2005-12-07
KR20010043641A (ko) 2001-05-25
JP2002515431A (ja) 2002-05-28
CZ299334B6 (cs) 2008-06-25
AR020074A1 (es) 2002-04-10
DE69909616D1 (de) 2003-08-21
EA005932B1 (ru) 2005-08-25
HUS1500023I1 (hu) 2017-03-28
HK1031691A1 (en) 2001-06-22
HRP20000778A2 (en) 2001-06-30
JP5872624B2 (ja) 2016-03-01
FR15C0035I1 (fr) 2015-06-26
PL194750B1 (pl) 2007-06-29
IL139130A0 (en) 2001-11-25

Similar Documents

Publication Publication Date Title
LU92699I2 (fr) Bazédoxifène, éventuellement sous la forme d'un sel pharmaceutiquement, acceptable tel que le sel d'acétate, et d'estrogènes conjugués
LU92428I2 (fr) Bosutinib, éventuellement sous la forme d'un sel pharmaceutiquement acceptable
LU91372I2 (fr) Retapamulin optionnellement sous forme d'un sel pharmaceutiquement acceptable (altargo)
LU91442I2 (fr) "Varénicline, optionnellement sous forme d'un sel pharmaceutiquement acceptable, y compris le sel tartrate"
LU92407I2 (fr) Afatinib, éventuellement sous la forme d'un sel pharmaceutiquement acceptable, y compris le sel dimaléate
LU91027I2 (fr) Dutasteride optionnellement sous forme d'un solvate pharmaceutiquement acceptable
LU90468I2 (fr) Zanamivir facultativement sous la forme d'un sel ou d'un derive pharmaceutiquement acceptable
LU91306I2 (fr) Mitratapide, optionnellement sous forme d'un sel d'addition acide pharmaceutiquement acceptable (YARVITAN)
HUP0003972A3 (en) Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
LU91585I2 (fr) Degarelix, éventuellement un sel pharmaceutiquement acceptable, tel que l'acétate (FIRMAGON)
CA2206233A1 (fr) Forme posologique mixte a base de cetirizine et de pseudoephedrine
LU91290I2 (fr) Céfovécine, optionnellement sous la forme d'un sel, dont le sel de sodium (CONVENIAr)
LU91673I2 (fr) "Dronédarone et ses dérivés pharmaceutiquement acceptables (MULTAQ)"
LU88842I2 (fr) Nebivolol optionnellement sous forme d'un sel ou d'un hydrate pharmaceutiquement acceptable en particulier hydroclorure de Nebivolol
LU91138I2 (fr) Glulisine d'insuline et ses dérivés pharmaceutiquement acceptables.
LU88809I2 (fr) Lamivudine facultativement sous la forme d'un sel pharmaceutiquement acceptable
LU91452I2 (fr) "Mycafungine et ses sels pharmaceutiquement acceptables(MYCAMINEr)"
LU90593I2 (fr) Quetiapine facutativement sous forme d'un sel pharmaceutiquement acceptabe
IS1812B (is) Meðferðaefnasambönd, lyfjafræðilega hæf sölt og samsetningar sem innihalda efnasamböndin, ásamt notkun þeirra
NO992944D0 (no) Virkestoffbµrer for avgivelse av apomorfin i munnhulen
AP9801423A0 (en) 2,3-substituted indole compounds as anti-inflammatory and analgesic agents
HUP0101475A3 (en) 4,5,6 and 7-indole and indoline derivatives, their preparation and use
ZA977807B (en) New pharmaceutically active compounds.
USD389582S (en) Support brace for knee or elbow
PL344978A1 (en) 4,5,6 and 7-indole and indoline derivatives, their preparation and use